As per the research report, the size of the Middle East and Africa Hormone Replacement Therapy Market is valued at USD 1.25 billion in 2023 and is predicted to reach USD 1.77 billion by 2028, growing at a CAGR of 7.24% during the forecast period 2023 to 2028.
Y-O-Y growth in the number of women suffering or on the verge of attaining menopause is one of the promising factors driving the hormone replacement therapy market in the MEA region. Lack of essential hormones leads to many health issues in women, such as osteoporosis, thyroid deficiency, vitamin-D deficiency, lethargy, etc. Around 46% of women between the ages of 40 to 60 years reported physicians using hormone replacement therapy (HRT) after menopause to keep them healthy.
As per the NIH statement released, more than half of the population will have postmenopausal women avail HRT by 2050. According to the United Nations (UN) World Population Ageing Report, as of 2050, the women population comprises 53.5% of the global population aged 65 years or over, with a life expectancy of 75 years in 2020.
Other factors which influence the HRT market in MEA are the rise of genetic abnormalities that affect the endocrine system in the body, increased prevalence of diseases such as polycystic ovarian syndrome, perimenopause, and transgender surgeries, etc. The Prader-Willi syndrome affects one in every 15,100 births, thereby boosting the demand for HRT therapy. According to the American Academy of Family Physicians, more than 3 million people receive testosterone treatment in the U.S annually. Furthermore, the survey was conducted for women aged between 30 to 60; nearly 47% of them had early onset of menopause in 2019.
In MEA region is prone to genetic disorders due to the high rate of birth ratio and consanguineous marriages. Following an investigation conducted by the World Health Organization (WHO) in 2019, almost 15.9 million infants are born prematurely, and roughly 85.5% of these babies require HRT to help with development. HRT is available in pills, patches, and injections, making them convenient for patient usage, thus driving the market growth rate.
Additionally, the growing R&D activities in the region to develop newer and better drugs to help treat hormonal disorders with lesser side effects and healthcare awareness are expected to impact the market over the projected period positively.
However, the high cost of HRT and risks associated with the use of HRT are anticipated to hamper the market growth. In addition, many regions in MEA are developing or underdeveloped. These regions face the issue of poor healthcare infrastructure and social stigma, which is expected to hamper the regional MEA hormone replacement therapy markets.
This research report on the Middle East & Africa Hormone Replacement Therapy Market has been segmented and sub-segmented into the following categories:
By Hormone Type:
By Route of Administration:
Geographically, the Middle East hormone replacement therapy market exhibited the highest growth in terms of revenue in the year 2022, owing to an increase in the large variety of drugs available in the market, innovations in the drug delivery systems, large population, increased funds for research and development and easy distribution of medication.
On the other hand, the Africa hormone replacement therapy market is expected to register a slow CAGR in terms of revenue during the forecast period. It is primarily due to a lack of knowledge about HRT, the vast spread of healthcare systems, and approval authorities. But, these African countries are anticipated to have a slow sluggish movement compared to the regions in the Middle East.
On the other hand, Middle Eastern countries such as Saudi Arabia, United Arab Emirates, and Qatar collectively have a market share of 55% in the overall market. In addition, these regions are home to many international pharmaceutical companies with their manufacturing units in these regions. These factors are anticipated to help the area develop and gather great sales in the upcoming years.
KEY MARKET PLAYERS
Leading companies leading in the MEA Hormone Replacement Therapy Market profiled in the report are Novartis, Abbott Laboratories, Pfizer, Mylan Laboratories, F. Hoffmann-La Roche, Merck & Co, Amgen, Eli Lily, Bayer, Novo Nordisk, Wyeth, Hisamitsu Pharmaceutical Co. Inc.,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com